Product details

Right from its inception in 1996, Indian pharma giant Bharat Biotech International Limited (BBIL) had been in news especially for its pathbreaking discoveries and development in the realm of pharma business. Vaccine had been a major focus of the company throughout its business journey. In a vaccine market fraught with challenges underlying development and supply access, innovation and discovery remained key to the progress of pharma companies dealing with such products. The COVID-19 pandemic made that even more apparent, and eventually many companies came forward with their own sort of products to optimise this huge market landscape worldwide. In India, BBIL made one such instance of discovery by floating the world's first ever nasal vaccine 'iNCOVACC'. While the vaccine was touted to have the potential to be a game changer, there were several challenges underlying it like any other vaccine. What advantages would iNCOVACC offer in comparison to the erstwhile subcutaneous vaccines? What drawbacks would it have to impede customers from receiving the vaccine? Would iNCOVACC finally emerge triumphant surmounting all the challenges it was likely to face?